Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases
详细信息 查看全文
- 作者：Nabil K. El Ayoubi ; Samia J. Khoury
- 关键词：Multiple sclerosis ; Autoimmune demyelination ; Biomarkers ; Disease progression ; Therapeutic response
- 刊名：Neurotherapeutics
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：14
- 期：1
- 页码：135-147
- 全文大小：
- 刊物主题：Neurosciences; Neurology; Neurosurgery; Neurobiology;
- 出版者：Springer US
- ISSN：1878-7479
- 卷排序：14
文摘
Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system. Only a few biomarkers are available in MS clinical practice, such as cerebrospinal fluid oligoclonal bands and immunoglobulin index, serum anti-aquaporin 4 antibodies, and serum anti-John Cunningham virus antibodies. Thus, there is a significant unmet need for biomarkers to assess prognosis, response to therapy, or potential treatment complications. Here we describe emerging biomarkers that are in development, focusing on those from peripheral blood. There are several limitations in the process of discovery and validation of a good biomarker, such as the pathophysiological complexity of MS and the technical difficulties in globally standardizing methods for sampling, processing, and conserving biological specimens. In spite of these limitations, ongoing international collaborations allow the exploration of many interesting molecules and markers to validate diagnostic, prognostic, and therapeutic-response biomarkers.